Compare Stocks: MESO, TGTX, APGE, and IMVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.49	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
IMVT Immunovant	$37.66 +0.8%	$40.43	$14.58 ▼ $45.42	$7.72B	0.81	1.11 million shs	1.11 million shs
MESO Mesoblast	$15.02 -3.0%	$16.18	$13.05 ▼ $21.50	$2.01B	2.12	197,731 shs	173,211 shs
TGTX TG Therapeutics	$54.00 +0.2%	$53.61	$26.76 ▼ $59.30	$8.25B	1.67	1.73 million shs	1.36 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	+0.39%	+58.46%	+266.24%
IMVT Immunovant	+0.80%	-4.05%	-9.95%	+12.05%	+133.04%
MESO Mesoblast	-2.97%	-13.28%	-3.72%	+9.24%	+1.35%
TGTX TG Therapeutics	+0.20%	-3.55%	+10.79%	+6.85%	+67.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.49	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
IMVT Immunovant	$37.66 +0.8%	$40.43	$14.58 ▼ $45.42	$7.72B	0.81	1.11 million shs	1.11 million shs
MESO Mesoblast	$15.02 -3.0%	$16.18	$13.05 ▼ $21.50	$2.01B	2.12	197,731 shs	173,211 shs
TGTX TG Therapeutics	$54.00 +0.2%	$53.61	$26.76 ▼ $59.30	$8.25B	1.67	1.73 million shs	1.36 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	+0.39%	+58.46%	+266.24%
IMVT Immunovant	+0.80%	-4.05%	-9.95%	+12.05%	+133.04%
MESO Mesoblast	-2.97%	-13.28%	-3.72%	+9.24%	+1.35%
TGTX TG Therapeutics	+0.20%	-3.55%	+10.79%	+6.85%	+67.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.16	Hold	$126.77	-6.14% Downside
IMVT Immunovant	2.55	Moderate Buy	$44.00	16.83% Upside
MESO Mesoblast	2.00	Hold	$39.00	159.65% Upside
TGTX TG Therapeutics	2.33	Hold	$63.00	16.67% Upside

Current Analyst Ratings Breakdown

Latest MESO, TGTX, APGE, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/7/2026	TGTX TG Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/1/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/27/2026	MESO Mesoblast	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00 ➝ $39.00
8/25/2026	IMVT Immunovant	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/4/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/4/2026	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $50.00
7/29/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
7/29/2026	IMVT Immunovant	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
MESO Mesoblast	$120.25M	16.22	N/A	N/A	$4.38 per share	3.43
TGTX TG Therapeutics	$616.29M	13.41	$2.81 per share	19.23	$4.08 per share	13.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
MESO Mesoblast	-$57.50M	-$0.28	N/A	41.72	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	$447.18M	$2.74	19.71	20.38	2.31	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest MESO, TGTX, APGE, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
IMVT Immunovant	N/A	7.27	7.27
MESO Mesoblast	0.19	2.43	2.09
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
IMVT Immunovant	47.08%
MESO Mesoblast	1.43%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
IMVT Immunovant	1.90%
MESO Mesoblast	18.80%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
MESO Mesoblast	108	129.88 million	105.46 million	Optionable
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable

MESO, TGTX, APGE, and IMVT Headlines

Recent News About These Companies

TG Therapeutics (NASDAQ:TGTX) Director Sells $274,800.00 in Stock

September 14 at 7:07 PM | marketbeat.com

Hsbc Holdings PLC Has $884,000 Holdings in TG Therapeutics, Inc. $TGTX

September 14 at 3:36 AM | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.17 Million in TG Therapeutics, Inc. $TGTX

September 11, 2026 | marketbeat.com

TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | quiverquant.comQ

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | globenewswire.com

TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Strong Sell" at Zacks Research

September 9, 2026 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Hold" by Analysts

September 7, 2026 | americanbankingnews.com

Wellington Management Group LLP Increases Stock Position in TG Therapeutics, Inc. $TGTX

September 6, 2026 | marketbeat.com

AXQ Capital LP Takes Position in TG Therapeutics, Inc. $TGTX

September 6, 2026 | marketbeat.com

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

September 3, 2026 | globenewswire.com

Corient Private Wealth LP Purchases Shares of 39,081 TG Therapeutics, Inc. $TGTX

September 3, 2026 | marketbeat.com

IBD stock of the day, TG Therapeutics, eyes breakout after topping early buy point

September 2, 2026 | msn.com

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

September 2, 2026 | zacks.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

September 2, 2026 | marketbeat.com

TGTX Stock Bounces Back as Analyst Downplays Threat from Novartis

September 1, 2026 | profitconfidential.comP

TGTX stock pares opening losses after analyst dismisses competition from Novartis

September 1, 2026 | msn.com

TG Therapeutics' (TGTX) Buy Rating Reaffirmed at HC Wainwright

September 1, 2026 | marketbeat.com

Jupiter Topco LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX

September 1, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $4.27 Million in TG Therapeutics, Inc. $TGTX

September 1, 2026 | marketbeat.com

Legal & General Group Plc Invests $17.70 Million in TG Therapeutics, Inc. $TGTX

August 31, 2026 | marketbeat.com

Man Group plc Makes New Investment in TG Therapeutics, Inc. $TGTX

August 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, TGTX, APGE, and IMVT Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$135.07 0.00 (0.00%)

As of 09/4/2026

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Immunovant NASDAQ:IMVT

$37.66 +0.30 (+0.80%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$37.64 -0.02 (-0.07%)

As of 09/14/2026 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Mesoblast NASDAQ:MESO

$15.02 -0.46 (-2.97%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$15.02 0.00 (-0.03%)

As of 09/14/2026 07:30 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

TG Therapeutics NASDAQ:TGTX

$54.00 +0.11 (+0.20%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$54.36 +0.36 (+0.66%)

As of 09/14/2026 07:57 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MESO, TGTX, APGE, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MESO, TGTX, APGE, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MESO, TGTX, APGE, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, TGTX, APGE, and IMVT Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Immunovant NASDAQ:IMVT

Mesoblast NASDAQ:MESO

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MESO, TGTX, APGE, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MESO, TGTX, APGE, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MESO, TGTX, APGE, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, TGTX, APGE, and IMVT Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Immunovant NASDAQ:IMVT

Mesoblast NASDAQ:MESO

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools